B
Bausch, Lupin, Oceanside
This settlement resolves claims that three pharmaceutical companies suppressed generic versions of Glumetza, benefiting those who purchased the drug directly.
ClosedUnited States-wideClaim status: Closed on May 29, 2022Payout: VariesNo longer claimable
About this settlement
The settlement compensates those who bought Glumetza directly from the defendants during the specified period, addressing alleged antitrust violations.
This class action settlement resolves allegations that Bausch, Lupin, and Oceanside suppressed generic alternatives to the diabetes drug Glumetza, affecting purchasers of both brand-name and generic versions.
Who qualifies
- Entities that purchased generic or brand-name Glumetza directly from Bausch, Lupin, or Oceanside.
- Purchases made between May 6, 2012 and August 15, 2020.
Varies
Claim status: Closed on May 29, 2022